COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure (NIHFT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01733017
Recruitment Status : Completed
First Posted : November 26, 2012
Last Update Posted : March 17, 2017
Sponsor:
Collaborator:
Ohio State University
Information provided by (Responsible Party):
Terry Lennie, University of Kentucky

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of is to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death.

Condition or disease Intervention/treatment Phase
Heart Failure Behavioral: Sodium reduction Dietary Supplement: omega 3 and lycopene supplements Dietary Supplement: rice bran oil capsules Behavioral: Generic dietary feedback from Phase 2

Detailed Description:
For a majority of patients with advanced heart failure, medical treatment is only partially effective in relieving heart failure symptoms. Therefore, it is recommended that palliative care be initiated soon after diagnosis. There is a need for complementary, nonpharmacologic interventions that could be easily implemented by health care providers to provide palliative care. Three major pathologic pathways underlying heart failure symptoms have been identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways. Clinical trials to date have only tested each nutrient individually. There is strong theoretical rationale that a combined intervention targeting all three nutrients would have substantial benefit in relieving symptoms in advanced heart failure. Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death. The aims of this placebo controlled study are 1) to determine the effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and fatigue) and health related quality of life at 3 and 6 months, and time to heart failure rehospitalization or all-cause death over 12 months from baseline; 2) compare dietary sodium intake, inflammation, and markers of oxidative stress between the nutrition intervention group and a placebo group at 3 and 6 months; and 3) compare body weight, serum lycopene, and erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and 6 months. A total of 150 patients with advanced heart failure will be randomized to either the nutrition intervention or placebo group (75 per group). The nutrition intervention group will receive a theory based education and skill building intervention designed to decrease dietary sodium intake to ~2 g per day. A research nurse will make 4 home visits and one follow-up telephone call over 6 months to provide the education-skill building intervention. The intervention group will take 3 omega-3 fatty acid capsules (350 mg eicosapentaenoic acid and 50 mg docosahexaenoic acid) and consume tomato juice or other tomato-based products containing 20-25 mg of lycopene daily for six months. The placebo group will receive the same number of visits and phone calls but only general nutrition information will be provided. They will take 3 placebo capsules containing rice oil (500 mg/capsule) and consume their choice of fruit juices that do not contain lycopene daily for six months. Data will be collected in person at baseline, 3 months, and 6 months by a research assistant blinded to the group assignment. Patients will be followed for an additional 6 months by telephone to collect longer term data on symptom burden and quality of life as well as heart failure hospitalization and all-cause mortality at 9 and 12 months.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Nutrition Intervention to Reduce Symptoms in Patients With Advanced Heart Failure
Study Start Date : November 2011
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Lycopene

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: sodium reduction, omega-3, lycopene
combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
 Behavioral: Sodium reduction
Teaching and skill building to reduce dietary sodium

Dietary Supplement: omega 3 and lycopene supplements
omega-3 fatty acid supplements and juices containing lycopene
Placebo Comparator: Control
Limited nutritional counseling, juice without lycopene, rice oil capsules
 Dietary Supplement: rice bran oil capsules
placebo capsules
Other Name: placebo

Behavioral: Generic dietary feedback from
Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
Other Name: attention control


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Event-Free Survival [ Time Frame: 12 months ]
    Combined endpoint of cardiac-related hospitalization and all cause mortality

  2. Symptom burden [ Time Frame: baseline, 3, 6, 9, and 12 months ]
    combined score of symptom severity, frequency, and distress for common symptoms of heart failure

  3. Quality of life [ Time Frame: baseline, 3, 6, 9, 12 months ]
    heart failure related quality of life


Secondary Outcome Measures :
  1. omega-3 index [ Time Frame: baseline, 3, 6, 9, 12 months ]
    the ratio of EPA plus DHA as a percentage of total fatty acids in the cell membrane of erythrocytes

  2. oxidative stress [ Time Frame: baseline, 3, 6, 9, 12 months ]
    serum levels of malondialdehyde and 8-iso-PGF2a isoprostane will serve as markers of increased lipid peroxidation due to oxygen free radical production exceeding antioxidant capacity

  3. Inflammation [ Time Frame: baseline, 3, 6, 9, 12 months ]
    Serum levels of tumor necrosis factor-alpha (TNFα), soluble TNF receptors: sTNFR1 and sTNFR2 will be measured as markers of proinflammatory cytokine activity; interleukin-10 (IL-10) will be measured as a marker of anti-inflammatory cytokine activity

  4. Lycopene [ Time Frame: baseline, 3, 6, 9, 12 months ]
    Plasma lycopene will be measured as a marker intervention effectiveness

  5. Sodium intake [ Time Frame: baseline, 3, 6, 9, 12 months ]
    Three 24-hour diet recall interviews at each timepoint will be used estimate sodium intake and to identify high sodium foods and eating patterns for the sodium reduction component of the intervention.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • chronic heart failure with either preserved or non-preserved ejection fraction
  • for chronic heart failure, have undergone evaluation of heart failure and optimization of medical therapy, for patients discharged from hospital for acute/newly diagnosed heart failure, have undergone evaluation of heart failure and optimization of medical therapy for at least 1 month post discharge
  • New York Heart Association functional classification of II, III or IV
  • have not been referred for heart transplantation
  • able to read and speak English
  • no cognitive impairment that precludes giving informed consent or ability to follow protocol instruction.

Exclusion Criteria:

  • BMI < 17 kg/m2 or > 46 kg/m2
  • co-existing illness documented in the medical record known to be associated with systemic inflammation decreased appetite or absorption, fatigue, edema, or weight loss
  • currently taking dietary supplements that contain lycopene or omega-3 fatty acids
  • allergy to rice bran oil
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01733017


Locations
Layout table for location information
United States, Kentucky
University of Kentucky, College of Nursing
Lexington, Kentucky, United States, 40536-0232
Norton Health Care
Louisville, Kentucky, United States, 40217
Sponsors and Collaborators
Terry Lennie
Ohio State University
Investigators
Layout table for investigator information
Principal Investigator: Terry A Lennie, PhD University of Kentucky College of Nursing
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Terry Lennie, PI, University of Kentucky
ClinicalTrials.gov Identifier: NCT01733017    
Other Study ID Numbers: R01NR013430 ( U.S. NIH Grant/Contract )
First Posted: November 26, 2012    Key Record Dates
Last Update Posted: March 17, 2017
Last Verified: March 2017
Keywords provided by Terry Lennie, University of Kentucky:
heart failure
nutrition therapy
symptoms
 quality of life
lycopene
omega-3 fatty acids
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Lycopene
Anti-Inflammatory Agents
Antioxidants
 Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Radiation-Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents